Longeveron Inc. (NASDAQ: LGVN) Full webcast at the at the Planet MicroCap Showcase: VEGAS | April 30 - May 2, 2024
For more information about Longeveron Inc., please visit: https://longeveron.com/
The interview may contain forward looking statements about Longeveron Inc. See Longeveron Inc.'s periodic filings with the Securities and Exchange Commission for more complete information.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines. The Company’s initial development compound, Lomecel-B, represents a pipeline in a product opportunity. The company has announced positive results from multiple clinical trials: Phase 2 in Alzheimer’s Disease, Phase 2 in Aging-related Frailty, Phase 1 in HLHS, a rare pediatric disease. The Company’s development programs for these 3 initial indications address market opportunities of ~$5+ billion, ~$4+ billion and up to ~$1 billion, respectively.
Based on positive initial data, the US FDA awarded the HLHS program with three distinct and important designations: Rare Pediatric Disease designation, Orphan drug designation, and Fast track designation, each of which offer benefits to our development and regulatory processes.
The Company anticipates completing enrollment in the on-going Phase 2 clinical trial in HLHS by year end 2024. The Company recently completed a capital to raise to fund continued clinical development.
Subscribe NOW to Planet MicroCap: http://bit.ly/1Q5Yfym
DISCLAIMER AND FORWARD LOOKING STATEMENT NOTICE
All information presented in all forms at the SNN Network Virtual Conference or in press releases, videos, emails, or otherwise posted on our website, stocknewsnow.com, SNN.Network, SNN Inc., SNN Network Virtual Conference and the Planet MicroCap Showcase or YouTube channel (the “Outlets”) is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Stock News Now, SNN Inc., SNN.Network, SNN Network Virtual Conference and the Planet MicroCap Showcase, and their representatives (“our,” “us,” and “we”) are not licensed brokers, broker/dealers, market makers, investment bankers, investment advisers, analysts, or underwriters. Any presentation on or at any of our Outlets is for informational purposes only and we do not recommend any company that may appear or present in any capacity on or at any of our Outlets. A company’s actual results could differ materially from those described in any forward-looking statements or presentation on or at any of our Outlets. Information within presentations or communications may contain “forward looking” statements. Forward-looking statements are based upon expectations, estimates, and projections at the time the statements are made and involve risks and uncertainties that could cause actual events to differ materially from those anticipated. Forward-looking statements may be identified through the use of words such as expects, anticipates, estimates, believes, or by statements indicating certain actions may, could, should or might occur. We receive cash compensation from presenters, sponsors, and participants who utilize our Outlets. We do not receive compensation for, and do not engage in, providing advice, making recommendations, issuing reports, or furnishing analyses on any of the companies, securities, strategies, or information presented. We may buy and sell securities in any company mentioned and may profit in the event those securities rise in value. There are risks involved in any investment. We are not analysts and investing in securities is for individuals with high risk tolerance and not for the general public. We recommend you consult with a professional investment adviser, broker, or legal counsel before purchasing or selling any securities referenced on or at any of our Outlets.
Информация по комментариям в разработке